Press "Enter" to skip to content

Medical cannabis for chronic pain blocked by NHS watchdog

Millie Hinton fro End our Pain
End our Pain campaign group says its a missed opportunity
Cannabis cannot be prescribed in England for NHS patients suffering chronic pain, the NHS funding watchdog has ruled, in a decision branded ‘devastating’ by campaigners.

New guidance, released over the weekend by the National Institute for Health and Care Excellence (Nice), says it can only be given to sufferers of certain forms of epilepsy and multiple sclerosis, but there is no evidence to show that cannabis is beneficial for people suffering long-term pain.

Charities had hoped that the drug would become widely available after it was decriminalised for medical use by Sajid Javid last November following high-profile campaigns involving children such as Alfie Dingley and Billy Caldwell, who both have hard-to-treat epilepsy.

But under the new ruling only people with two rare types of epilepsy, Lennox-Gastaut and Dravet syndrome, will be able to access the cannabis-derived drug Epidyolex through the NHS, meaning both Billy and Alfie will miss out.

Without Nice approval only a tiny handful of doctors are qualified and willing to prescribe medical cannabis, meaning they are virtually impossible to obtain in practice.

Millie Hinton, from the campaign End Our Pain, said the guidelines were ‘a massive missed opportunity’ for thousands of people with a range of conditions.

“It is particularly devastating that there is no positive recommendation that the NHS should allow prescribing of whole plant medical cannabis containing both CBD (cannabidiol) and THC in appropriate cases of intractable childhood epilepsy,” she said

“It is this kind of whole plant extract that has been shown to be life-transforming for a significant number of children, including those involved in the high-profile cases of last year which led to medical cannabis being legalised.”

Evidence medicinal cannabis works

Families of children with epilepsy are paying thousands of pounds every month on private prescriptions for medical cannabis and say the youngsters show dramatic reductions in seizure rates.

Charities warned that Nice was too focussed on evidence from randomised control trials, while ignoring the everyday evidence from people taking the drugs.

Simon Wigglesworth, deputy chief executive at Epilepsy Action, welcomed the decision to recommend Epidyolex, however, he said there were many thousands of people with other complex and treatment-resistant epilepsies who could potentially benefit from cannabis-based medicines.

Only around 8,0000 to 9,000 people in the UK suffer Lennox-Gastaut and Dravet syndromes compared with the 500,000 people who suffer from all forms of epilepsy.

Mr Wigglesworth said: “Though this is disappointing, we appreciate that clinical research is vital to ensure that any treatment recommended for use in the NHS is safe and effective.

“We are aware of ongoing efforts to bring forward research into cannabis-based medicines for epilepsy, including those containing THC, at pace.”

However Nice did recommend the cannabis-dervied nasal spray Sativex for muscle spasms in multiple sclerosis (MS).

And in August the body also approve Nabilone, a synthetic cannabis-based medicine for cancer patients struggling with side-effects of chemotherapy.

Genevieve Edwards, director of external affairs at the MS Society, said: “We’ve been campaigning for access to Sativex for years, and it’s brilliant Nice has finally listened.

“These guidelines are an important first step, but don’t go far enough. No cannabis-based treatments have been recommended to treat pain, a common symptom of MS.

“Additionally, because Sativex will be funded by local bodies – who might not have the resource they need to prescribe it – even more people could miss out.”

She said evidence shows cannabis-based treatments could help around 10,000 people with MS get relief from pain and spasms when other treatments have not worked.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *